One study analyzed asparaginase therapy in participants with a conglomerate of primarily solid tumors: melanoma, small cell lung cancer, non-small cell lung cancer, sarcoma, colon cancer, cholangiocarcinoma, renal cell carcinoma, bladder cancer, and malignancy with unknown primary. Here, ASPG is linked to hereditary clear cell renal cell carcinoma.